Table 1 Patient anticancer therapy (ACT) regimens March 1 to June 30, 2020.
From: Urological cancer patients receiving treatment during COVID-19: a single-centre perspective
Type | Treatment | Steroid | Standard duration (days) | Cycles | Patients |
|---|---|---|---|---|---|
IO | Atezoliazumab | — | — | 51 | 12 |
IO | Pembrolizumab | — | — | 8 | 2 |
CHEMO | Carbo/Etoposide | DEX | 3 | 7 | 2 |
CHEMO | Cis1/Gem1 + 8 | DEX | 3 | 17 | 6 |
CHEMO | Cis1 + 8/Gem1 + 8 | DEX | 3 | 33 | 15a |
CHEMO | Docetaxel | DEX/PRED | 3/21 | 28 | 10 |
CHEMO | Gemc/Carbo | DEX | 3 | 7 | 3 |
CHEMO | Paclitaxel | DEX | 3 | 7 | 2a |
TRIAL | POTOMAC (Durvalumab) | — | — | 18 | 4 |
TRIAL | JAVELIN (Avelumab) | — | — | 4 | 1 |
TRIAL | NIAGARA (Cis/Gem) | — | — | 5 | 2 |
TRIAL | STRONG (Durvalumab) | — | — | 4 | 1 |
TRIAL | ASTELLAS (Enfortumab) | — | — | 4 | 1 |
TRIAL | ASTELLAS (Paclitaxel) | DEX | 3 | 2 | 1 |
Total | — | — | — | 195 | 61a |
